# Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma

> **NCT01538472** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 40 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Y Zevalin
- **DRUG:** In Zevalin
- **DRUG:** Rituxan
- **DRUG:** BCNU
- **DRUG:** VP -16
- **DRUG:** Ara-C
- **DRUG:** Melphalan
- **PROCEDURE:** Stem Cell Infusion
- **DRUG:** G-CSF

## Key facts

- **NCT ID:** NCT01538472
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01538472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01538472, "Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01538472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*